Recordati Industria Chimica e Farmaceutica Management
Management criteria checks 3/4
Recordati Industria Chimica e Farmaceutica's CEO is Rob Koremans, appointed in Dec 2021, has a tenure of 3.92 years. total yearly compensation is €3.26M, comprised of 19.3% salary and 80.7% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth $44.09K. The average tenure of the management team and the board of directors is 3.9 years and 6.2 years respectively.
Key information
Rob Koremans
Chief executive officer
€3.3m
Total compensation
| CEO salary percentage | 19.26% |
| CEO tenure | 3.9yrs |
| CEO ownership | 0.0004% |
| Management average tenure | 3.9yrs |
| Board average tenure | 6.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | €407m |
| Mar 31 2025 | n/a | n/a | €418m |
| Dec 31 2024 | €3m | €628k | €417m |
| Sep 30 2024 | n/a | n/a | €423m |
| Jun 30 2024 | n/a | n/a | €387m |
| Mar 31 2024 | n/a | n/a | €389m |
| Dec 31 2023 | €2m | €590k | €389m |
| Sep 30 2023 | n/a | n/a | €375m |
| Jun 30 2023 | n/a | n/a | €389m |
| Mar 31 2023 | n/a | n/a | €340m |
| Dec 31 2022 | €2m | €590k | €312m |
| Sep 30 2022 | n/a | n/a | €331m |
| Jun 30 2022 | n/a | n/a | €330m |
| Mar 31 2022 | n/a | n/a | €393m |
| Dec 31 2021 | €154k | n/a | €386m |
Compensation vs Market: Rob's total compensation ($USD3.76M) is below average for companies of similar size in the US market ($USD13.47M).
Compensation vs Earnings: Rob's compensation has increased by more than 20% in the past year.
CEO
Rob Koremans (63 yo)
Dr. Robert Koremans, also known as Rob, M.D. serves as Chief Executive Officer and Director of Recordati Industria Chimica e Farmaceutica S.p.A. since December 1, 2021. Dr. Koremans served as Chief Executi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.9yrs | €3.26m | 0.00036% $ 44.1k | |
| Group CFO & Executive Director | 6yrs | €1.45m | 0.0056% $ 679.7k | |
| Executive Director | no data | no data | no data | |
| Executive Director | 6.8yrs | no data | no data | |
| VP & Head of Investor Relations | 1.8yrs | no data | no data | |
| Group Chief Legal Officer | 2.6yrs | no data | no data | |
| Group Communications Director | no data | no data | no data | |
| Executive VP of Corporate Development | 9.2yrs | no data | no data | |
| Group Chief People & Culture Officer | 1.7yrs | no data | no data | |
| Executive Vice President of Specialty & Primary Care Business Unit | 4.8yrs | no data | no data | |
| Executive Vice President of Rare Diseases Business Unit | no data | no data | no data | |
| Executive VP of Research & Development and Chief Medical Officer | 2.1yrs | no data | no data |
Experienced Management: RICF.Y's management team is considered experienced (3.9 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 3.9yrs | €3.26m | 0.00036% $ 44.1k | |
| Group CFO & Executive Director | 3.8yrs | €1.45m | 0.0056% $ 679.7k | |
| Executive Director | 6.9yrs | no data | no data | |
| Executive Director | 6.9yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Non-Executive Chairman | 27.6yrs | €315.00k | no data | |
| Independent Director | less than a year | no data | no data | |
| Non-Executive Director | 3.9yrs | €90.00k | no data | |
| Independent Non-Executive Director | 5.6yrs | €80.00k | no data | |
| Statutory Auditor | 11.8yrs | €25.00k | no data | |
| Chairman of Statutory Auditor Board | 8.6yrs | no data | no data | |
| Independent Non-Executive Director | 6.8yrs | €85.00k | no data |
Experienced Board: RICF.Y's board of directors are considered experienced (6.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/01 08:25 |
| End of Day Share Price | 2025/10/21 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Recordati Industria Chimica e Farmaceutica S.p.A. is covered by 25 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Paola Saglietti | Banca Akros S.p.A. (ESN) |
| Charles Pitman | Barclays |
| Charles Pitman | Barclays |